NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference

  NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment
  Conference

Rodman & Renshaw Global Investment Conference 2013

Business Wire

WALTHAM, Mass. -- September 3, 2013

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on
management of chronic pain and peripheral neuropathies, today announced that
Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is
scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference
at the Millennium Broadway Hotel, New York, NY on September 8-10, 2013. Dr.
Gozani intends to provide an update on the Company’s business activities
including the SENSUS™Pain Management System, which is an electrical nerve
stimulator uniquely designed for controlling chronic pain caused by diabetic
neuropathy.

NeuroMetrix's presentation is scheduled for Monday, September 9, 2013 at 2:50
pm (Eastern Daylight Time) in Room 7.03, 7^th Floor. A live audio webcast will
be available on the investor relations section of the corporate website -
www.neurometrix.com. This webcast will be archived after the live event.

About NeuroMetrix

NeuroMetrixis a medical device company that develops and markets home use and
point-of-care devices for the treatment and management of chronic pain and
peripheral neuropathies. The Company is presently focused on diabetic
neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at$14 billionintheUnited States. The
company markets the SENSUS™ Pain Management System for treating chronic pain,
focusing on physicians managing patients with painful diabetic neuropathy. The
company also markets the DPNCheck^®device, which is a rapid, accurate, and
quantitative point-of-care test for diabetic neuropathy. This product is used
to detect diabetic neuropathy at an early stage and to guide treatment. For
more information, please visithttp://www.neurometrix.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.